Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
gemcitabine + cisplatin + lenvatinib is a combination therapy regimen being evaluated for the treatment of advanced or unresectable intrahepatic cholangiocarcinoma. The regimen consists of lenvatinib, an oral multi-kinase inhibitor, combined with the chemotherapy doublet of gemcitabine and cisplatin (GC). Lenvatinib functions by inhibiting multiple receptor tyrosine kinases involved in angiogenesis and tumor growth, including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. Gemcitabine is a nucleoside metabolic inhibitor that disrupts DNA synthesis, while cisplatin is a platinum-based agent that forms DNA cross-links, leading to apoptosis. This specific combination is being investigated in clinical trials led by Shanghai Zhongshan Hospital to improve outcomes in patients with biliary tract cancers.
- Other names
- GC combined LenvatinibLenvatinib plus GC
02
Targets
DNADNA polymerase familyFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on gemcitabine + cisplatin + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + lenvatinib.